Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines

Vaccine

Volumn 32, Issue 18, 2014, Pages 2100-2108

  Ma, Cuiqing ^a,f   Li, Ye ^a   Wang, Lili ^a   Zhao, Guangyu ^b   Tao, Xinrong ^c   Tseng, Chien Te K ^c,d   Zhou, Yusen ^b   Du, Lanying ^a   Jiang, Shibo ^a,e  

^a NEW YORK BLOOD CENTER   (United States)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c University of Texas Medical Branch School of Medicine   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^e BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^f HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

MERS CoV; Mucosal immune response; Neutralizing antibody; Receptor binding domain; Spike protein; Systemic immune response

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; MONTANIDE ISA 51; NEUTRALIZING ANTIBODY; RECOMBINANT MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS RECEPTOR BINDING DOMAIN FC PROTEIN; RECOMBINANT PROTEIN; RECOMBINANT RECEPTOR; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CORONAVIRUS INFECTION; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR BINDING; SARS CORONAVIRUS; SUBCUTANEOUS IMMUNOTHERAPY; VACCINATION;

MERS-COV; MUCOSAL IMMUNE RESPONSE; NEUTRALIZING ANTIBODY; RECEPTOR-BINDING DOMAIN; SPIKE PROTEIN; SYSTEMIC IMMUNE RESPONSE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CORONAVIRUS; FEMALE; HEK293 CELLS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; LUNG; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS; SPIKE GLYCOPROTEIN, CORONAVIRUS; SPLEEN; VIRAL VACCINES;

EID: 84896545485     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.02.004     Document Type: Article

References (44)

1. Zaki A.M., van B.S., Bestebroer T.M., Osterhaus A.D., Fouchier R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012, 367:1814-1820.
2. Memish Z.A., Zumla A.I., Assiri A. Middle East respiratory syndrome coronavirus infections in health care workers. N Engl J Med 2013, 369:884-886.
3. Assiri A., McGeer A., Perl T.M., Price C.S., Al Rabeeah A.A., Cummings D.A., et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013, 369:407-416.
4. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003, 426:450-454.
5. Raj V.S., Mou H., Smits S.L., Dekkers D.H., Muller M.A., Dijkman R., et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013, 495:251-254.
6. Gierer S., Bertram S., Kaup F., Wrensch F., Heurich A., Kramer-Kuhl A., et al. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol 2013, 87:5502-5511.
7. Muller M.A., Raj V.S., Muth D., Meyer B., Kallies S., Smits S.L., et al. Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. MBio 2012, 3.
8. Chan J.F., Chan K.H., Choi G.K., To K.K., Tse H., Cai J.P., et al. Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J Infect Dis 2013, 207:1743-1752.
9. Bai B., Lu X., Meng J., Hu Q., Mao P., Lu B., et al. Vaccination of mice with recombinant baculovirus expressing spike or nucleocapsid protein of SARS-like coronavirus generates humoral and cellular immune responses. Mol Immunol 2008, 45:868-875.
10. Du L., Zhao G., Chan C.C., Sun S., Chen M., Liu Z., et al. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology 2009, 393:144-150.
11. He Y., Lu H., Siddiqui P., Zhou Y., Jiang S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 2005, 174:4908-4915.
12. Du L., Zhao G., Lin Y., Sui H., Chan C., Ma S., et al. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. J Immunol 2008, 180:948-956.
13. Lee J.S., Poo H., Han D.P., Hong S.P., Kim K., Cho M.W., et al. Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice. J Virol 2006, 80:4079-4087.
14. Du L., He Y., Zhou Y., Liu S., Zheng B.J., Jiang S. The spike protein of SARS-CoV - a target for vaccine and therapeutic development. Nat Rev Microbiol 2009, 7:226-236.
15. Chen Y., Rajashankar K.R., Yang Y., Agnihothram S.S., Liu C., Lin Y.L., et al. Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus. J Virol 2013, 87:10777-10783.
16. Mou H., Raj V.S., van Kuppeveld F.J., Rottier P.J., Haagmans B.L., Bosch B.J. The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol 2013, 87:9379-9383.
17. Wang N., Shi X., Jiang L., Zhang S., Wang D., Tong P., et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 2013, 23:986-993.
18. Du L., Zhao G., Kou Z., Ma C., Sun S., Poon V.K., et al. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol 2013, 87:9939-9942.
19. Li Y., Du L., Qiu H., Zhao G., Wang L., Zhou Y., et al. A recombinant protein containing highly conserved hemagglutinin residues 81-122 of influenza H5N1 induces strong humoral and mucosal immune responses. Biosci Trends 2013, 7:129-137.
20. Du L., Zhao G., He Y., Guo Y., Zheng B.J., Jiang S., et al. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine 2007, 25:2832-2838.
21. He Y., Zhou Y., Liu S., Kou Z., Li W., Farzan M., et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun 2004, 324:773-781.
22. Du L., Zhao G., Sun S., Zhang X., Zhou X., Guo Y., et al. A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection. PLoS ONE 2013, 8:e53568.
23. Martyn J.C., Cardin A.J., Wines B.D., Cendron A., Li S., Mackenzie J., et al. Surface display of IgG Fc on baculovirus vectors enhances binding to antigen-presenting cells and cell lines expressing Fc receptors. Arch Virol 2009, 154:1129-1138.
24. Chen H., Xu X., Jones I.M. Immunogenicity of the outer domain of a HIV-1 clade C gp120. Retrovirology 2007, 4:33.
25. Du L., Kou Z., Ma C., Tao X., Wang L., Zhao G., et al. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS ONE 2013, 8:e81587.
26. Du L., Zhao G., Lin Y., Chan C., He Y., Jiang S., et al. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. Vaccine 2008, 26:1644-1651.
27. Tao X., Hill T.E., Morimoto C., Peters C.J., Ksiazek T.G., Tseng C.T. Bilateral entry and release of Middle East respiratory syndrome coronavirus induces profound apoptosis of human bronchial epithelial cells. J Virol 2013, 87:9953-9958.
28. Cauchemez S., Van K.M., Riley S., Donnelly C., Fraser C., Ferguson N. Transmission scenarios for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and how to tell them apart. Euro Surveill 2013, 18.
29. Breban R., Riou J., Fontanet A. Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk. Lancet 2013, 382:694-699.
30. Almazan F., DeDiego M.L., Sola I., Zuniga S., Nieto-Torres J.L., Marquez-Jurado S., et al. Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate. MBio 2013, 4:e00650-e713.
31. Du L., Zhao G., Li L., He Y., Zhou Y., Zheng B.J., et al. Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells. Biochem Biophys Res Commun 2009, 384:486-490.
32. Chan J.F., Li K.S., To K.K., Cheng V.C., Chen H., Yuen K.Y. Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic?. J Infect 2012, 65:477-489.
33. van B.S., de G.M., Lauber C., Bestebroer T.M., Raj V.S., Zaki A.M., et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 2012, 3:e00473-12.
34. Song F., Fux R., Provacia L.B., Volz A., Eickmann M., Becker S., et al. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus ankara efficiently induces virus-neutralizing antibodies. J Virol 2013, 87:11950-11954.
35. Ichinohe T., Watanabe I., Ito S., Fujii H., Moriyama M., Tamura S., et al. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol 2005, 79:2910-2919.
36. Ichinohe T., Kawaguchi A., Tamura S., Takahashi H., Sawa H., Ninomiya A., et al. Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. Microbes Infect 2007, 9:1333-1340.
37. Frasca D., Diaz A., Romero M., Mendez N.V., Landin A.M., Blomberg B.B. Effects of age on H1N1-specific serum IgG1 and IgG3 levels evaluated during the 2011-2012 influenza vaccine season. Immun Ageing 2013, 10:14.
38. Guery B., Poissy J., El M.L., Sejourne C., Ettahar N., Lemaire X., et al. Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission. Lancet 2013, 381:2265-2272.
39. Drosten C., Seilmaier M., Corman V.M., Hartmann W., Scheible G., Sack S., et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis 2013, 13:745-751.
40. Zhao K., Yang B., Xu Y., Wu C. CD8+ T cell response in HLA-A*0201 transgenic mice is elicited by epitopes from SARS-CoV S protein. Vaccine 2010, 28:6666-6674.
41. Fan Y.Y., Huang Z.T., Li L., Wu M.H., Yu T., Koup R.A., et al. Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection. Arch Virol 2009, 154:1093-1099.
42. Huang J., Ma R., Wu C.Y. Immunization with SARS-CoV S DNA vaccine generates memory CD4+ and CD8+ T cell immune responses. Vaccine 2006, 24:4905-4913.
43. Kakimi K., Isobe M., Uenaka A., Wada H., Sato E., Doki Y., et al. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Int J Cancer 2011, 129:2836-2846.
44. Do Y., Didierlaurent A.M., Ryu S., Koh H., Park C.G., Park S., et al. Induction of pulmonary mucosal immune responses with a protein vaccine targeted to the DEC-205/CD205 receptor. Vaccine 2012, 30:6359-6367.